Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

NCT01510561 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01510561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01510561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Withdrawn
Start date
March 31, 2012
Completion date
September 30, 2015
Enrollment
0 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma, metastatic pancreatic cancer, pancreatic cancer